article Open AccessTop 1% cited

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine · 2019 · Vol. 381(21) · pp. 1995–2008

John J.V. McMurray✉(Copenhagen University Hospital)Scott D. Solomon(Copenhagen University Hospital)Silvio E. Inzucchi(Copenhagen University Hospital)Lars Køber(Copenhagen University Hospital)Mikhail Kosiborod(Copenhagen University Hospital)Felipe A. Martínez(Universidad Nacional de Córdoba)Piotr Ponikowski(Copenhagen University Hospital)Marc S. Sabatine(Brigham and Women's Hospital)Inder S. Anand(University of Minnesota)Jan Bělohlávek(Charles University)Michael Böhm(Copenhagen University Hospital)Chern‐En Chiang(National Yang Ming Chiao Tung University)Vijay Chopra(Medanta The Medicity)Rudolf A. de Boer(University Medical Center Groningen)Akshay S. Desai(Copenhagen University Hospital)Mirta Díez(Copenhagen University Hospital)Jarosław Dróżdż(Copenhagen University Hospital)Andrej Dukát(Copenhagen University Hospital)Junbo Ge(Sun Yat-sen University)Jonathan G. Howlett(University of Calgary)Tzvetana Katova(Copenhagen University Hospital)Masafumi Kitakaze(Copenhagen University Hospital)Charlotta Ljungman(Swedish Academy)Béla Merkely(Semmelweis University)José Carlos Nicolau(Copenhagen University Hospital)Eileen O’Meara(Montreal Heart Institute)Mark C. Petrie(Copenhagen University Hospital)Pham Nguyễn Vinh(Copenhagen University Hospital)Morten Schou(Copenhagen University Hospital)С. Н. Терещенко(Copenhagen University Hospital)Subodh Verma(St. Michael's Hospital)Claes Held(Uppsala University)David L. DeMets(University of Wisconsin–Madison)Kieran F. Docherty(Copenhagen University Hospital)Pardeep S. Jhund(Copenhagen University Hospital)Olof Bengtsson(Copenhagen University Hospital)Mikaela Sjöstrand(Copenhagen University Hospital)Anna-Maria Langkilde(Copenhagen University Hospital)

View via DOI Full-text PDF

Abstract

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).

Diabetes Treatment and Management Pancreatic function and diabetes Diabetes Management and ResearchDapagliflozinEjection fractionHeart failureCardiologyInternal medicineFraction (chemistry)MedicineChemistryDiabetes mellitusEndocrinology

MeSH terms

Kaplan-Meier EstimateSodium-Glucose Transporter 2 InhibitorsAgedBenzhydryl CompoundsCardiovascular AgentsCardiovascular DiseasesCombined Modality TherapyDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlucosidesHeart FailureGlycated HemoglobinHospitalizationHumans